These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

251 related items for PubMed ID: 23079690

  • 1. Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years.
    McClung MR, Balske A, Burgio DE, Wenderoth D, Recker RR.
    Osteoporos Int; 2013 Jan; 24(1):301-10. PubMed ID: 23079690
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet.
    McClung MR, Miller PD, Brown JP, Zanchetta J, Bolognese MA, Benhamou CL, Balske A, Burgio DE, Sarley J, McCullough LK, Recker RR.
    Osteoporos Int; 2012 Jan; 23(1):267-76. PubMed ID: 21947137
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data.
    McClung MR, Zanchetta JR, Racewicz A, Roux C, Benhamou CL, Man Z, Eusebio RA, Beary JF, Burgio DE, Matzkin E, Boonen S, Delmas P.
    Osteoporos Int; 2013 Jan; 24(1):293-9. PubMed ID: 22752050
    [Abstract] [Full Text] [Related]

  • 4. Risedronate dosing before breakfast compared with dosing later in the day in women with postmenopausal osteoporosis.
    Kendler DL, Ringe JD, Ste-Marie LG, Vrijens B, Taylor EB, Delmas PD.
    Osteoporos Int; 2009 Nov; 20(11):1895-902. PubMed ID: 19296144
    [Abstract] [Full Text] [Related]

  • 5. Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety results.
    Delmas PD, Benhamou CL, Man Z, Tlustochowicz W, Matzkin E, Eusebio R, Zanchetta J, Olszynski WP, Recker RR, McClung MR.
    Osteoporos Int; 2008 Jul; 19(7):1039-45. PubMed ID: 18087660
    [Abstract] [Full Text] [Related]

  • 6. Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate.
    Brown JP, Roux C, Ho PR, Bolognese MA, Hall J, Bone HG, Bonnick S, van den Bergh JP, Ferreira I, Dakin P, Wagman RB, Recknor C.
    Osteoporos Int; 2014 Jul; 25(7):1953-61. PubMed ID: 24676847
    [Abstract] [Full Text] [Related]

  • 7. Efficacy, tolerability and safety of once-monthly administration of 75mg risedronate in Japanese patients with involutional osteoporosis: a comparison with a 2.5mg once-daily dosage regimen.
    Hagino H, Kishimoto H, Ohishi H, Horii S, Nakamura T.
    Bone; 2014 Feb; 59():44-52. PubMed ID: 24184313
    [Abstract] [Full Text] [Related]

  • 8. Bone safety with risedronate: histomorphometric studies at different dose levels and exposure.
    Recker RR, Ste-Marie LG, Chavassieux P, McClung MR, Lundy MW.
    Osteoporos Int; 2015 Jan; 26(1):327-37. PubMed ID: 25304456
    [Abstract] [Full Text] [Related]

  • 9. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study.
    Boonen S, Orwoll ES, Wenderoth D, Stoner KJ, Eusebio R, Delmas PD.
    J Bone Miner Res; 2009 Apr; 24(4):719-25. PubMed ID: 19049326
    [Abstract] [Full Text] [Related]

  • 10. Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial.
    Välimäki MJ, Farrerons-Minguella J, Halse J, Kröger H, Maroni M, Mulder H, Muñoz-Torres M, Sääf M, Snorre Øfjord E.
    Clin Ther; 2007 Sep; 29(9):1937-49. PubMed ID: 18035193
    [Abstract] [Full Text] [Related]

  • 11. Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis.
    Roux C, Reid DM, Devogelaer JP, Saag K, Lau CS, Reginster JY, Papanastasiou P, Bucci-Rechtweg C, Su G, Sambrook PN.
    Osteoporos Int; 2012 Mar; 23(3):1083-90. PubMed ID: 21975559
    [Abstract] [Full Text] [Related]

  • 12. Comparison of the effects of once-monthly versus once-daily risedronate in postmenopausal osteoporosis: a phase II, 6-month, multicenter, randomized, double-blind, active-controlled, dose-ranging study.
    Ste-Marie LG, Brown JP, Beary JF, Matzkin E, Darbie LM, Burgio DE, Racewicz AJ.
    Clin Ther; 2009 Feb; 31(2):272-85. PubMed ID: 19302900
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis.
    Delmas PD, McClung MR, Zanchetta JR, Racewicz A, Roux C, Benhamou CL, Man Z, Eusebio RA, Beary JF, Burgio DE, Matzkin E, Boonen S.
    Bone; 2008 Jan; 42(1):36-42. PubMed ID: 17920005
    [Abstract] [Full Text] [Related]

  • 14. A novel monthly dosing regimen of risedronate for the treatment of postmenopausal osteoporosis: 2-year data.
    McClung MR, Benhamou CL, Man Z, Tlustochowicz W, Zanchetta JR, Eusebio R, Balske AM, Matzkin E, Olszynski WP, Recker R, Delmas PD.
    Calcif Tissue Int; 2013 Jan; 92(1):59-67. PubMed ID: 23150144
    [Abstract] [Full Text] [Related]

  • 15. Phase II/III, randomized, double-blind, parallel-group study of monthly delayed-release versus daily immediate-release risedronate tablets in Japanese patients with involutional osteoporosis.
    Soen S, Kishimoto H, Hagino H, Sone T, Ohishi H, Fujimoto T, Sasaki E, Tanaka S, Sugimoto T.
    J Bone Miner Metab; 2020 Jan; 38(1):86-98. PubMed ID: 31420748
    [Abstract] [Full Text] [Related]

  • 16. Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis.
    Harris ST, Watts NB, Li Z, Chines AA, Hanley DA, Brown JP.
    Curr Med Res Opin; 2004 May; 20(5):757-64. PubMed ID: 15140343
    [Abstract] [Full Text] [Related]

  • 17. The efficacy and safety of weekly 35-mg risedronate dosing regimen for Chinese postmenopausal women with osteoporosis or osteopenia: 1-year data.
    Gu JM, Wang L, Lin H, Chen DC, Tang H, Jin XL, Xia WB, Hu YQ, Fu WZ, He JW, Zhang H, Wang C, Yue H, Hu WW, Liu YJ, Zhang ZL.
    Acta Pharmacol Sin; 2015 Jul; 36(7):841-6. PubMed ID: 26051110
    [Abstract] [Full Text] [Related]

  • 18. Fracture risk remains reduced one year after discontinuation of risedronate.
    Watts NB, Chines A, Olszynski WP, McKeever CD, McClung MR, Zhou X, Grauer A.
    Osteoporos Int; 2008 Mar; 19(3):365-72. PubMed ID: 17938986
    [Abstract] [Full Text] [Related]

  • 19. Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density.
    Naylor KE, Bradburn M, Paggiosi MA, Gossiel F, Peel NFA, McCloskey EV, Walsh JS, Eastell R.
    Osteoporos Int; 2018 Jun; 29(6):1407-1417. PubMed ID: 29525970
    [Abstract] [Full Text] [Related]

  • 20. Risedronate once monthly: a potential new regimen for the treatment of postmenopausal osteoporosis.
    Moro-Alvarez MJ, Díaz-Curiel M.
    Clin Interv Aging; 2008 Jun; 3(2):227-32. PubMed ID: 18686745
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.